Methylphenidate prodrug

Drug Profile

Methylphenidate prodrug

Alternative Names: D-threo-methylphenidate prodrug - KemPharm; KP 415; KP 484

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator KemPharm
  • Class Behavioural disorder therapies; Phenylacetates; Piperidines; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Attention-deficit hyperactivity disorder

Highest Development Phases

  • Phase I Attention-deficit hyperactivity disorder

Most Recent Events

  • 10 Aug 2017 Phase-I clinical trials in Attention-deficit hyperactivity disorder (In volunteers) in USA (PO) before August 2017
  • 10 Aug 2017 Interim pharmacokinetics data from a phase I trial in Attention deficit hyperactivity disorder released by KemPharm
  • 10 Aug 2017 KemPharm completes a phase I trial in Attention deficit hyperactivity disorder (In volunteers) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top